What is the Share Price of Zydus Lifesciences Ltd?

Zydus Lifesciences Ltd share price is ₹1,064.40 As on 13 October, 2024|01:36

Home
>
Stocks
>
Zydus Lifesciences Ltd

Zydus Lifesciences Ltd

Q: What is the Market Cap of Zydus Lifesciences Ltd?

The Market Cap of Zydus Lifesciences Ltd is ₹107,104 As on 13 October, 2024|01:36

Q: What is PE Ratio of Zydus Lifesciences Ltd?

The P/E ratio of Zydus Lifesciences Ltd is 25.7 As on 13 October, 2024|01:36

Q: What is PB Ratio of Zydus Lifesciences Ltd?

The PB ratio of Zydus Lifesciences Ltd is 5.40 As on 13 October, 2024|01:36

₹ 1,064.40 +7.40 (0.70%)
Updated on 12-10-2024 6:56 AM

Stock Rating

Pros 5

Cons 2

Option Chain

Price Performance

Day's Low
₹1,051.60

Day's High
₹1,070.50

₹ 1,064.40

52-w low
₹567.75

52-w high
₹1,324.30

1,064.40

Day's open
₹1,062.60
Previous close
₹1,057
VWAP
₹1,063.26
Lower price band
₹958
Upper price band
₹1,170.80

Today's Market Action

The last traded share price of Zydus Lifesciences Ltd was 1,064.40 up by 0.70% on the NSE. Its last traded stock price on BSE was 1,064.20 up by 0.68%. The total volume of shares on NSE and BSE combined was 653,266 shares. Its total combined turnover was Rs 69.44 crores.

Medium and Long Term Market Action

Zydus Lifesciences Ltd hit a 52-week high of 1,324.30 on 09-08-2024 and a 52-week low of 567.75 on 26-10-2023. The stock price of Zydus Lifesciences Ltd is down by -4% over the last one month. It is up by 77.1% over the last one year. Don't forget to check the full stock price history in the table below.

Fundamentals

Market Cap (Cr): 107104
Book Value (₹):
Stock P/E:
Revenue (Cr):
Total Debt (Cr):

Face Value (₹):
Roce (%):
ROE (%):
Earnings (Cr):
Promoter’s Holdings (%):

EPS (₹):
Debt to Equity:
Dividend Yield (%):
Cash (Cr):

Mutual fund holdings and trends

FUND NAME	Quantity	Monthly Change (Qty)

Shareholding Pattern

Similar Stocks

Company	Price	Market Cap (Cr)	P/E

About

Data not available.

FAQ's

What is Share Price of Zydus Lifesciences Ltd?

What is the Market Cap of Zydus Lifesciences Ltd?

What is PE Ratio of Zydus Lifesciences Ltd?

What is PB Ratio of Zydus Lifesciences Ltd?

What is the CAGR of Zydus Lifesciences Ltd?

How to Buy Zydus Lifesciences Ltd Share?

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Cash Flow)

Standalone Financial Performace In Graph(Cash Flow)

Pros

Momentum Strength
The stock is currently exhibiting strong momentum, & is showing consistent strong relative strength.
Above Average Sustainable RoE
The company generates a sustainable return on equity greater than the expected cost of capital which implies that the underlying business can create and compound value over a period time due to it's ability to generate above average return on capital.
High Pricing Power
The business enjoys a relatively high pricing power and is able to withstand competitive pressure which works as a great moat for equity shareholders of the company.
Zero Debt
The company has almost nil to negligible debt to equity ratio of 0.04. Considering the fact that the business is debt free, equity shareholders shall carry lower risk of holding the stock.
Above Average Growth Rate
The company is estimated to grow its earnings at a reasonable rate over the next few years which will drive shareholder value creation

Cons

Capital Intensive Business
The company operates an extremely capital intensive business with a low Asset turnover ratio of 1.29. A low asset turnover ratio negatively impacts RoE and reduces shareholder returns. Also due to the capital intensive nature of business, growth of the business would need to be funded either via increasing borrowings or diluting shareholders, both of which shall negatively impact shareholder value and returns.
Poor Working Capital Cycle
The company has a very poor working capital cycle of 166 days which requires very high investments in working capital. This reduces free cash flow generation for the business and negatively impacts shareholder value and returns.

Valuation Analysis

Margin of safety
(13/10/2024)

Margin of Safety Index: High

82.61%

82.61% People are bullish about Zydus Lifesciences Ltd

17.39%

17.39 % People are bearish about Zydus Lifesciences Ltd

What is your opinion about this Stock?

Historical Data

Date	Open	High	Low	Close	Volume	Daily Change %